Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders

European Journal of Pharmacology

Volumn 297, Issue 3, 1996, Pages 299-306

  Ge, Jian ^a   Barnes, Nicholas M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alzheimer's disease; Angiotensin AT1 receptor; Angiotensin AT2 receptor; Brain, human; Huntington's disease; Losartan; Parkinson's disease; PD123177; 125I Sar1,Ile8 Angiotensin II

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; IODINE 125; LOSARTAN; LOSARTAN POTASSIUM; RADIOLIGAND; ANGIOTENSIN RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; BRAIN HOMOGENATE; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; TEMPORAL CORTEX; BRAIN; CLASSIFICATION; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, ANGIOTENSIN;

EID: 0029670896     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00762-8     Document Type: Article

References (37)

1. Allen, A.M., D.P. MacGregor, S.Y. Chai, G.A. Donnan, S.J. Kaczmarcayk, K. Richardson, R.M. Kalnins, J. Ireton and F.A.O. Mendelsohn, 1992, Angiotensin II receptor binding associated with nigro-striatal dopaminergic neurones in human basal ganglia, Ann. Neurol. 32, 42.
2. Arregui, A., L.L. Iversen, G.S. Spokes and P.C. Emson, 1979, Alterations in postmortem brain angiotensin-converting enzyme activity and some neuropeptides in Huntington's disease, in: Advances in Neurology, eds. T.N. Chase, N.S. Wexler and A. Barbean (Raven Press) 23, 517.
3. Arregui, A., E.K. Perry, M. Rossor and B.E. Tomlinson, 1982, Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas, J. Neurochem. 38, 1490.
4. Ball, M.J., M. Fisman, V. Hachinski, W. Blume, A. Fox, V.A. Kral, A.J. Kirchen and H. Merskey, 1985, A new definition of Alzheimer's disease: a hippocampal dementia, Lancet I, 14.
5. 3H]acetylchoIine from rat entorhinal cortex, Brain Res. 491, 136.
6. Barnes, J.M., N.M. Barnes, B. Costall, Z.P. Horovitz, J.W. Ironside, R.J. Naylor and T.J. Williams, 1990a, Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition, Brain Res. 507, 341.
7. Barnes, N.M., B. Costall, M.E. Kelly, D.A. Murphy and R.J. Naylor, 1990b, Anxiolytic-like action of DuP753, a potent and selective non-peptide angiotensin II receptor antagonist, NeuroReport 1, 20.
8. Barnes, N.M., B. Costall, M.E. Kelly, D.A. Murphy and R.J. Naylor, 1990c, Cognitive enhancing action of DuP753 detected in a mouse habituation paradigm, NeuroReport 1, 239.
9. Barnes, J.M., N.M. Barnes, B. Costall, J. Ge, M.E. Kelly, D.A. Murphy and R.J. Naylor, 1991a, Anxiolytic-like and cognitive enhancing action of the non-peptide angiotensin II receptor antagonist, DuP753, in: Current Advances in ACE Inhibition 2, eds. G.A. MacGregor and P.S. Sever (Churchill Livingston, Edingburgh) p. 260.
10. Barnes, N.M., B. Costall, M.E. Kelly, D.A. Murphy and R.J. Naylor, 1991b, Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm, NeuroReport 2, 351.
11. Barnes, N.M., C.H.K. Cheng, B. Costall, R.J. Naylor, T.J. Williams and C.M. Wischik, 1991c, Angiotensin converting enzyme activity is increase in temporal cortex from patients with Alzheimer's disease, Eur. J. Pharmacol. 200, 289.
12. Barnes, J.M., L.J. Steward, P.C. Barber and N.M. Barnes, 1993, Identification and characterisation of angiotensin II receptor subtypes in human brain, Eur. J. Pharmacol. 230, 251.
13. Bartus, R.T., R.L. Dean, B. Beer and A.S. Lippa, 1982, The cholinergic hypothesis of geriatric memory dysfunction, Science 217, 408.
14. Bottari, S.P., M. Gasparo, M. Steckelings and N.R. Levens, 1993, Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications, Frontiers Neuroendocrinol. 14, 2, 123.
15. Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding, Anal. Biochem. 72, 248.
16. 1 receptors, Br. J. Pharmacol. 110, 92P.
17. 8]angiotensin II and selective nonpeptide antagonist, Biochem. Biophys. Res. Commun. 171, 813.
18. Costall, B., A.M. Domeney, P.A. Gerrard, Z.P. Horovitz, M.E. Kelly, R.J. Naylor and D.M. Tomkins, 1990, Effects of captopril and SQ 29,852 on anxiety-related behaviours in rodent and marmoset, Pharmacol. Biochem. Behav. 36, 13.
19. Gehlert, D.R., S.L. Gackenheimer and D.A. Schober, 1991, Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain, Neurosci. 44, 501.
20. 8]angiotensin: periventricular sites of the anterior third ventricle, Neuroendocrinology 44, 15.
21. Jellinger, K., 1990, Changes in subcortical nuclei in Parkinson's disease, in: Function and Dysfunction in the Basal Ganglia, eds. A.J. Franks, J.W. Ironside, R.H.S. Mindham, R.J. Smith, E.G.S. Spokes and W. Winlow (Manchester University Press) p. 69.
22. Koning, C.H., M.A. Kuiper, Ph. Scheltens, A.M. Grjpma, W. Van Pelt and E.Ch. Wolters, 1993, Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with 'probable' Alzheimer's disease, Eur. J. Clin. Chem. Clin. Biochem. 31, 495.
23. Mendelsohn, F.A.O., T.A. Jenkins and S.F. Berkovic, 1993, Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats, Brain Res. 613, 221.
24. Peach, M.J., 1977, Renin-angiotensin system: biochemistry and mechanisms of action, Physiol. Rev. 57, 313.
25. Phillips, M.I., 1987, Functions of angiotensin in the central nervous system, Annu. Rev. Physiol. 49, 413.
26. Price, K.S., I.J. Parley and O. Hornykiewicz, 1979, Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine, in: Advance in Biochemistry and Psychopharmacology, eds. P.J. Roberts et al. (Raven Press, New York) 19, 293.
27. Quarrel, Q., 1991, The neurology of Huntington's disease, in: Huntington's Disease, eds. P.S. Harper (W.B. Saunders Co. Ltd., London) p. 141.
28. Reid, J.L. and P.C. Rubin, 1987, Peptides and central neural regulation of the circulation, Physiol. Rev. 67, 725.
29. Reynolds, G.P. and S.J. Pearson, 1992, Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes, J. Neurologi. Sci. 113, 230.
30. Rogers, J. and J.H. Morrison, 1985, Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease, J. Neurosci. 5, 2801.
31. Rowe, B.P., D.L. Saylor and R.C. Speth, 1992, Analysis of angiotensin II receptor subtypes in individual rat brain nuclei, Neuroendocrinology 55, 563.
32. Schinke, M., H.N. Doods, D. Ganten, W. Wienen and M. Entzeroth, 1991, Characterization of rat intestinal angiotensin II receptors, Eur. J. Pharmacol. 204, 165.
33. 3H]dopamine in rat striatal slices, Neurosci. Lett. 15, 153.
34. Timmermans, P.B.M.W.M., P.C. Wang, A.T. Chiu and W.F. Herblin, 1991. Nonpeptide angiotensin II receptor antagonists, Trends Pharmacol. Sci. 12, 55.
35. Unger, T., E. Badoer, D. Ganten, R.E. Lang and R. Rettig, 1988, Brain angiotensin: pathways and pharmacology, Circulation 77, 1, 40.
36. Usinger, P., F.J. Hock, G. Wiemer, H.J. Gerhards, R. Henning and H. Urbach, 1988, Hoe 288: indications on the memory-enhancing effects of a peptidase inhibitor, Drug Dev. Res. 14, 315.
37. Weiner, M.F., F.J. Bonte, R. Tintner, N. Ford, D. Svetlik and T. Riall, 1992. Angiotensin-converting enzyme inhibitor lack acute effect on cognition or brain blood flow in Alzheimer's disease, Drug Dev. Res. 26, 467.